1383481-65-9

Basic information

• Product Name: C₂₁H₂₀ClN₅
• CAS NO: 1383481-65-9
• Molecular Weight: 377.876
• Mol File: 1383481-65-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₁H₂₀ClN₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₁H₂₀ClN₅(1383481-65-9)
• EPA Substance Registry System: C₂₁H₂₀ClN₅(1383481-65-9)

Safety Data

• Hazardous Substances Data: 1383481-65-9(Hazardous Substances Data)

Upstream product

• 1003-03-8 Cyclopentamine 
• 1383481-57-9 C₁₁H₁₁ClIN₃ 
• 1383481-56-8 2-chloro-N-cyclopentyl-5-((trimethylsilyl)ethynyl)pyrimidin -4-amine 
• 1211442-87-3 [2-chloro-5-(3,3-diethoxy-prop-1-ynyl)-pyrimidin-4-yl]-cyclopentyl amine 
• 733039-20-8 5-bromo-2-chloro-N-cyclopentylaminopyrimidine-4-amine 
• 761446-45-1 1-(phenylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1383481-58-0 C₁₁H₁₁ClIN₃ 

Downstream Products

• 1383481-70-6 C₃₂H₃₇N₉O 

Relevant articles and documents

Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors

This Letter reports the optimization of a pyrrolopyrimidine series as dual inhibitors of Aurora A/B kinases. This series derived from a pyrazolopyrimidine series previously reported as inhibitors of aurora kinases and CDKs. In an effort to improve the selectivity of this chemotype, we switched to the pyrrolopyrimidine core which allowed functionalization on C-2. In addition, the modeling rationale was based on superimposing the structures of Aurora-A kinase and CDK2 which revealed enough differences leading to a path for selectivity improvement. The synthesis of the new series of pyrrolopyrimidine analogs relied on the development of a different route for the two key intermediates 7 and 19 which led to analogs with both tunable activity against CDK1 and maintained cell potency.